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Abstract
Objective To provide evidence to support updated guidelines for the
management of pregnant women with hereditary thrombophilia in order
to reduce the risk of a first venous thromboembolism (VTE) in pregnancy.
Design Systematic review and bayesian meta-analysis.
Data sources Embase, Medline, Web of Science, Cochrane Library,
and Google Scholar from inception through 14 November 2016.
Review methods Observational studies that reported on pregnancies
without the use of anticoagulants and the outcome of first VTE for women
with thrombophilia were eligible for inclusion. VTE was considered
established if it was confirmed by objective means, or when the patient
had received a full course of a full dose anticoagulant treatment without
objective testing.
Results 36 studies were included in the meta-analysis. All thrombophilias
increased the risk for pregnancy associated VTE (probabilities ≥91%).
Regarding absolute risks of pregnancy associated VTE, high risk
thrombophilias were antithrombin deficiency (antepartum: 7.3%, 95%
credible interval 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%),
protein C deficiency (antepartum: 3.2%, 0.6% to 8.2%; post partum:
5.4%, 0.9% to 13.8%), protein S deficiency (antepartum: 0.9%, 0.0% to
3.7%; post partum: 4.2%; 0.7% to 9.4%), and homozygous factor V
Leiden (antepartum: 2.8%, 0.0% to 8.6%; post partum: 2.8%, 0.0% to
8.8%). Absolute combined antepartum and postpartum risks for women
with heterozygous factor V Leiden, heterozygous prothrombin G20210A
mutations, or compound heterozygous factor V Leiden and prothrombin
G20210A mutations were all below 3%.
Conclusions Women with antithrombin, protein C, or protein S deficiency
or with homozygous factor V Leiden should be considered for antepartum
or postpartum thrombosis prophylaxis, or both. Women with heterozygous
factor V Leiden, heterozygous prothrombin G20210A mutation, or
compound heterozygous factor V Leiden and prothrombin G20210A
mutation should generally not be prescribed thrombosis prophylaxis on
the basis of thrombophilia and family history alone. These data should
be considered in future guidelines on pregnancy associated VTE risk.
Introduction
Venous thromboembolism (VTE) is a major cause of pregnancy
related mortality1 2 and morbidity.3 VTE increases the risk of
permanent work related disability.4 Pregnancy increases the risk
of VTE in women fivefold to sixfold compared with age
matched controls.5 A positive family history for VTE further
increases the risk of pregnancy associated VTE 3.7-fold to
8.5-fold.6 7 Hereditary thrombophilia increases the risk of
pregnancy associated VTE up to 34-fold as reported by
Robertson et al in a systematic review including nine studies in
2006.8 Women are at an even higher risk for pregnancy
associated VTE in the six week postpartum period than during
pregnancy.
Absolute risk estimates of pregnancy associated VTE in women
with inherited thrombophilia mentioned in the American College
of Chest Physicians’ (ACCP) 2012 guidelines9 are based on a
limited number of cohort studies, and on an estimated baseline
VTE incidence multiplied by the odds ratios found in the
systematic review by Robertson et al.8 To date, no systematic
review or meta-analysis of absolute risk of pregnancy associated
VTE for women with thrombophilia has been published. Data
on risks of pregnancy associated VTE of compound
heterozygous factor V Leiden and prothrombin G20210A
mutation were not included in Robertson’s systematic review8
nor in the ACCP 2012 guidelines.9 As several studies on
thrombophilia and the risk of pregnancy associated VTE have
been published since 2006, an updated systematic review is
needed.
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Owing to limitations of the data available, guidelines for the
management of pregnant women with thrombophilia without
previous VTE differ considerably in their recommendations on
the use of thrombosis prophylaxis in the antepartum and
postpartum period.10 We performed an updated systematic
review and meta-analysis of studies on the relative and absolute
risks of pregnancy associated VTE in women with established
thrombophilia with no previous VTE to improve prevention of
pregnancy associated VTE in women.
Methods
The results of this systematic review and meta-analysis are
reported according to PRISMA guidelines.11 Details of the study
protocol are available in web appendix 1.
Data sources and searches
We systematically searched Embase, Medline, Web of Science,
Cochrane Library, and Google Scholar using a search strategy
constructed with the aid of a biomedical information specialist
(see web appendix 1 for details). References were checked for
additional articles missed by the primary search. The search
was first performed on 8 February 2016 and updated on 14
November 2016. Two authors (FNC and JJD) independently
selected articles for further reading. All articles were included
or excluded based on predefined selection criteria. Decisions
were based on consensus. Authors were contacted by email if
clarification was required.
Study selection
Case-control studies or cohort studies that contained extractable
information on the number of pregnancies and the outcome first
VTE were eligible. The studies contained information on
participants with specific inherited thrombophilias: antithrombin
deficiency, protein C deficiency, protein S deficiency, factor V
Leiden mutation (heterozygous or homozygous), prothrombin
G20210A mutation (heterozygous or homozygous), or
compound heterozygous factor V Leiden and prothrombin
G20210A mutation. Studies were included if the definition of
VTE was compatible with the following: VTE was considered
established if it was confirmed by objective means, or when the
patient had received a full course of a full dose anticoagulant
treatment without objective testing. Studies contained data on
pregnancies without use of anticoagulants. To minimise bias
we excluded cohort studies that did not separate proband data
from family member data. Studies were peer reviewed, written
in English, and published between 1970 and 2016. In the event
of duplicate publications, we chose the most informative report.
Data extraction and quality assessment
Data were extracted in duplicate using standardised forms.
Disagreements were resolved by consensus. VTE events were
deep venous thrombosis, pulmonary embolism, deep venous
thrombosis and pulmonary embolism, or non-separately
described superficial venous thrombosis events. Separately
reported superficial venous thrombosis events were not
considered as VTE events. In case-control studies, we recorded
the number of women with the selected thrombophilia for each
number of cases and for each number of respective controls.
For each group in cohort studies, we recorded the number of
pregnancy associated first VTE events for each number of
pregnancies. These events were classified as antepartum or post
partum if this information was available. For the calculation of
odds ratios, in case-control studies we compared women with
separate thrombophilias with their respective study controls and
in cohort studies we compared women with separate
thrombophilias with women without established thrombophilia
(non-carriers). Information on women in cohort studies who
carried less established thrombophilic abnormalities, such as
MTHFR (methylenetetrahydrofolate reductase) mutations8 and
associated hyperhomocysteinemia, was analysed in the
non-carriers group. A family history of VTE influences the VTE
risk,6 12 so we classified studies as family studies or non-family
studies. Quality assessment was performed using the
Newcastle-Ottawa Scale (NOS) scoring (see web appendix 1).13
Statistical analysis
Bayesian random effects meta-analysis was used to estimate
odds ratios and absolute risks of VTE for each thrombophilia.
See web appendix 2 for more information on the bayesian
analysis used. Risk distributions are summarised by the median
as a point estimate and 95% credible intervals (ie, area under
the posterior distribution). Relatively non-informative priors
were used for all variables (see web appendix 2). In addition,
we estimated the probability of odds ratios and absolute risks
being above thresholds of interest.14 For calculation of the
absolute risk of postpartum VTE, we disregarded pregnancies
that had resulted in a VTE antepartum. To handle partly missing
information on time of VTE events, bayesian multiple
imputation was used (ie, the assumption that data were missing
completely at random). Computations and graphics were
performed with R.15 All bayesian computations were performed
using the Marcov chain Monte Carlo (MCMC) sampler through
Jags interface in R.16 MCMC sampling was run for each analysis
for 1 500 000 iterations after discarding the first 50 000
iterations (burn-in).
Data synthesis and analysis
As a different absolute risk of pregnancy associated VTE was
expected in non-carriers in family studies compared with
non-family studies, we used the labels family study and
non-family study as covariates in the analyses. In addition, the
analyses of the absolute risks of pregnancy associated VTE in
family studies and non-family studies are shown separately for
women with thrombophilia and for non-carriers. We performed
a sensitivity analysis by comparing the results of meta-analysis
of all studies with the results of meta-analysis of studies
remaining after elimination of studies not requiring objective
VTE diagnoses (odds ratio only) and after elimination of low
quality studies (defined as studies with a score below the median
on the NOS). For the odds ratios, we also carried out separate
case-control and cohort study analyses.
Patient involvement
No patients were involved in setting the research question or
the outcome measures, nor were they involved in developing
plans for design or implementation of the study. No patients
were asked to advise on interpretation or writing up of results.
There are no plans to disseminate the results of the research to
study participants or the relevant patient community. It was not
evaluated whether the studies included in the review had any
patient involvement.
Results
Summary of selection process
The search yielded 2695 articles. We identified another eight
articles for full review by checking references. After removal
of duplicates, 1593 articles were screened on title and abstract
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for further reading. Figure 1⇓ shows that a total of 118 articles
were selected for full review. Eighty two articles were excluded
for various reasons. Finally, 36 articles were selected for the
systematic review and meta-analysis.
Most studies covered a selection of the thrombophilias of
interest. The following numbers of studies were included on
the separate thrombophilias: antithrombin deficiency: four cohort
studies 17-20 and seven case-control studies21-27; protein C
deficiency: three cohort studies18-20 and eight case-control
studies21-29; protein S deficiency: three cohort studies18-20 and
eight case-control studies21-29; heterozygous factor V Leiden: 17
cohort studies7-45 and 11 case-control studies21-48; homozygous
factor V Leiden: six cohort studies7-49 and six case-control
studies21-48; heterozygous prothrombin G20210A mutation: five
cohort studies31-51 and 10 case-control studies21-48; homozygous
prothrombin G20210A mutation: one cohort study31 and three
case-control studies22-47; and compound heterozygous factor V
Leiden and prothrombin G20210A mutation: three cohort
studies39-49 and five case-control studies.21-47
Study characteristics
Web appendix 1 summarises the study characteristics. The total
number of pregnancies reported was 41 297, of which 5994
were in women with thrombophilia and 35 303 were in controls
or non-carriers. Of 36 studies, 12 were case-control studies, 15
were family cohort studies, and nine were non-family cohort
studies. Fourteen cohort studies were retrospective and 10 were
prospective. Of 24 cohort studies, 15 contained data on the time
of venous thromboembolism (VTE) events (antepartum or post
partum).
Risk of bias within studies
Web appendix 2 provides details of study quality assessment
as reflected by Newcastle-Ottawa Scale (NOS) scoring. The
median of NOS scores was 8 in both case-control and cohort
studies. Two cohort studies had no non-carrier group.18 41 Most
studies required an objective VTE diagnosis. The six studies
that allowed antithrombotic treatment without an objective VTE
diagnosis were not given a star in the quality assessment score
for selection of cases in case-control studies or for assessment
of outcome in cohort studies.7-50
Relative risk of pregnancy associated VTE
Table 1⇓ summarises the meta-analyses of the relative risks of
pregnancy associated VTE expressed as odds ratios. High odds
ratios were found for antithrombin deficiency (9.5, 95% credible
interval 1.6 to 31.9), protein C deficiency (9.3, 2.1 to 43.1),
protein S deficiency (7.0, 1.3 to 21.9), heterozygous factor V
Leiden mutation (6.4, 4.0 to 9.7), homozygous factor V Leiden
(35.8, 0.4 to 137.8), heterozygous prothrombin G20210A
mutation (5.1, 2.6 to 9.8), and compound heterozygous factor
V Leiden and prothrombin G20210A mutation (21.2, 1.6 to
89.0). Odds ratios were high but not statistically significant for
homozygous prothrombin G20210A mutation (21.1, 0.0 to
727.4). Web appendix 1 shows the forest plots for the odds ratio
calculations.
Absolute risk of pregnancy associated VTE
Table 2⇓ summarises the results of the meta-analyses of absolute
risks of pregnancy associated VTE for women with the separate
thrombophilias. The forest plots are given in web appendix 1.
Antithrombin, protein C, and protein S
deficiency
Only family studies were available for women with
antithrombin, protein C, and protein S deficiency. The highest
absolute risk of pregnancy associated VTE was found in
antithrombin deficient women (overall: 16.6%, 95% credible
interval 0.0% to 45.1%; antepartum: 7.3%, 1.8% to 15.6%; post
partum: 11.1%, 3.7% to 21.0%). Absolute risks were also high
for protein C deficiency (overall: 7.8%, 0.0% to 33.8%;
antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to
13.8%), and protein S deficiency (overall: 4.8%, 0.0% to 20.0%;
antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%, 0.7% to
9.4%).
Heterozygous and homozygous factor V
Leiden mutations
For women with heterozygous factor V Leiden mutation, the
absolute risk of pregnancy associated VTE was 1.1% overall
(95% credible interval 0.3% to 1.9%), 0.4% antepartum (0.1%
to 0.9%), and 2.0% postpartum (0.9% to 3.7%). The absolute
risk of pregnancy associated VTE derived from family studies
(2.4%) was higher than the risk derived from non-family studies
(0.4%).
For women with homozygous factor V Leiden mutation, the
absolute risk of pregnancy associated VTE was 6.2% overall
(95% credible interval 0.0% to 18.0%), 2.8% antepartum (0.0%
to 8.6%), and 2.8% post partum (0.0% to 8.8%). The absolute
risk of pregnancy associated VTE derived from family studies
(8.3%, 95% credible interval 0.0% to 29.6%) was higher than
the risk derived from non-family studies (5.6%, 0.0% to 34.3%).
Heterozygous and homozygous prothrombin
G20210A mutation
For women with heterozygous prothrombin G20210A mutation,
the absolute risk of pregnancy associated VTE was 0.9% overall
(95% credible interval 0.2% to 2.0%), 0.0% antepartum (0.0%
to 0.2%), and 0.9% post partum (0.2% to 2.0%). The absolute
risk of pregnancy associated VTE derived from family studies
(1.0%) was higher than the risk derived from non-family studies
(0.8%).
The one woman with homozygous prothrombin G20210A
mutation in the cohort study that qualified for inclusion did not
have a VTE event.
Combined heterozygous factor V Leiden and
prothrombin G20210A mutation
For women with heterozygous factor V Leiden and prothrombin
G20210A combined, the absolute risk of pregnancy associated
VTE in family studies was 2.5% overall (95% credible interval
0.0% to 9.5%). Data were too limited for an analysis of
antepartum and postpartum risk. No non-family studies without
thrombosis prophylaxis were found.
Antepartum versus postpartum VTE
Of 143 VTE events in cohort studies, information on time of
occurrence was available for 115 events. Thirty events (26%)
occurred antepartum and 85 (74%) occurred post partum. In
high risk thrombophilias (antithrombin deficiency, protein C
deficiency, protein S deficiency, and homozygous factor V
Leiden mutation) 17/44 events (44%) occurred antepartum, and
in low risk thrombophilias (heterozygous factor V Leiden,
heterozygous prothrombin G20210A mutation, or compound
heterozygous factor V Leiden and prothrombin G20210A
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mutation) or non-carriers 13/71 events (18%) occurred
antepartum. For each thrombophilia the absolute risk of
pregnancy associated VTE antepartum or post partum was
calculated (table 2⇓). As posterior distributions of the absolute
risk estimates were skewed, the probabilities of absolute risks
of pregnancy associated VTE being above the thresholds of 1%
and 3% were calculated to aid in clinical decision making (table
2⇓). We were not able to perform this analysis for compound
heterozygous factor V Leiden and prothrombin G20210A
mutation or for the family and non-family subgroups for
homozygous factor V Leiden mutation or heterozygous
prothrombin G20210A mutation owing to a lack of data.
Risk of bias across studies: additional and
sensitivity analyses
In family studies on non-carriers the absolute risk of pregnancy
associated VTE was higher (0.5%, 95% credible interval 0.2%
to 1.0%) than in the non-family studies (0.1%, 0.0% to 0.2%).
Table 1⇓ shows the results of the sensitivity analyses of relative
risks. To investigate if study type (case-control v cohort) had
an impact on odds ratio estimates, we performed separate
analyses for these study types. Higher estimates were found in
case-control studies for protein C deficiency, heterozygous
factor V Leiden mutation, homozygous factor V Leiden
mutation, and compound heterozygous factor V Leiden and
prothrombin G20210A mutation. For antithrombin deficiency
the odds ratio in cohort studies was higher. Table 1⇓ shows that
removing studies which did not require objective VTE diagnoses
had only limited impact on odds ratio estimates. To investigate
if study quality had an impact on relative risk estimates of
pregnancy associated VTE, the meta-analyses were repeated
including only high quality studies (NOS score ≥8, ie, the
median score). Table 1⇓ shows that similar odds ratio
distributions and point estimates were obtained. The small
number of pregnancies and VTE events for each study and
variable results for each study cause skewed posterior
distributions and hence statistical insignificance in the odds
ratios for some thrombophilias. When calculating the probability
of the odds ratios being greater than 1 in the high quality studies,
for all thrombophilias we found a probability of 91% for protein
S deficiency and 99% or higher for the others.
Table 2⇓ summarises the results of most sensitivity analyses of
absolute risk estimates. To investigate if study quality had an
impact on absolute risk estimates of pregnancy associated VTE,
the meta-analyses were repeated including only high quality
studies. Using this criterion, cohorts that lacked a non-carriers
group (n=2) were also excluded. Web appendix 1 shows the
results of all individual meta-analyses of high quality studies
for all investigated thrombophilias. Overall, removal of low
quality studies had an impact on the point estimates of absolute
risks of pregnancy associated VTE, which are generally lower
in studies with a high NOS score (≥8). However, the 95%
credible intervals for all studies and for high quality studies
remain similar for most thrombophilias.
Discussion
Women with hereditary thrombophilia have an increased risk
of pregnancy associated venous thromboembolism (VTE). High
absolute risk estimates for pregnancy associated VTE were
found for women with the rare thrombophilias of antithrombin
deficiency, protein C deficiency, protein S deficiency, and
homozygous factor V Leiden mutation, but not for compound
heterozygous factor V Leiden and prothrombin G20210A
mutation. For women with the more prevalent heterozygous
factor V Leiden mutation or heterozygous prothrombin
G20210A mutation the absolute risk was mildly increased, and
limited to women with a positive family history. Most VTE
occurred in the postpartum period. The absolute risk of
pregnancy associated VTE was higher for non-carriers in family
studies compared with non-carriers in non-family studies.
Sensitivity analysis showed that point estimates and the 95%
credible intervals of absolute risks were influenced by study
quality in family cohort studies only. Compared with American
College of Chest Physicians’ (ACCP) guidelines,9 our
meta-analysis of high quality studies shows markedly higher
absolute risk estimates for women with antithrombin deficiency
and protein C deficiency, and more conservative absolute risk
estimates for women with protein S deficiency. In addition, high
risks of pregnancy associated VTE were found for women with
combined heterozygous factor V Leiden and prothrombin
G20210A mutation. Antithrombin deficiency, protein C
deficiency, protein S deficiency, homozygous factor V Leiden
mutation, and homozygous prothrombin G20210A mutation
should all be considered high risk thrombophilias for pregnant
women based on our assessment of all studies and only high
quality studies. In contrast, absolute risk estimates for
heterozygous factor V Leiden and for heterozygous prothrombin
G20210A mutation were lower compared with ACCP
guidelines.9
Strengths and weaknesses of this study
Bayesian statistics enabled us to perform both a meta-analysis
of the relative risks and the first meta-analysis of the absolute
risks of pregnancy associated VTE in women with
thrombophilia. It allowed for calculating the antepartum and
postpartum risk using multiple imputation when only partial
information was available, and for calculating the probability
for risks being greater than treatment thresholds. It is useful to
take specific thresholds of interest into account, especially with
skewed risk distributions as is the case in all analyses. 95%
Credible intervals are not constructed the same way as in classic
statistics (see web appendix 2). Therefore, the probability of
the odds ratio being greater than 1 can still be above 99%, even
though the 95% credible intervals include 1 (table 1⇓). In
contrast with classic statistics, bayesian statistics provide
inferences that are conditional on the data and are exact.
Therefore, interpretation of bayesian analysis is more
straightforward and more direct in terms of belief (eg, a 95%
credible interval for a risk is that region in which we believe
the risk to be with a probability of 95%). Classic statistics’ 95%
confidence intervals describe the range where the exact risk
estimate will be should the same experiment be repeated
infinitely. Bayesian random effects meta-analysis is better able
to compute study specific credible intervals depending on data
from other studies.52 Bayesian analysis is the most suited method
for this dataset of rare events: classic statistical methods cannot
deal with infinite variance of individual studies, when event
rates in a group of 0 or 100% occur.14 Most classic
meta-analytical software automatically replace zero with a fixed
value (typically 0.5). This usually has the undesirable effect of
biasing study estimates.53 Regarding the studies included in our
review, this issue would have occurred in all odds ratio estimates
if classic meta-analysis software would have been used, but this
poses no problem for bayesian analysis.
Odds ratio estimates correlate poorly with absolute risk estimates
in our meta-analysis. This can be explained by differences of
VTE risk in non-carriers. The absolute risk of pregnancy
associated VTE for non-carriers from family studies is sixfold
higher than the risk from non-family studies. Only the absolute
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risk of pregnancy associated VTE found in the non-family study
non-carriers resembles the risk in the general population of
0.08% found by Simpson et al,54 whereas most odds ratio data
stem from family studies and case-control studies. Controls
from those studies do not resemble the general population, and
therefore odds ratios are not easily translated to absolute risks
in the general population.
The sensitivity analysis shows the impact of study quality on
point estimates of VTE risk. This is most clear for the absolute
risk of pregnancy associated VTE in women with deficiencies
of antithrombin, protein C, or protein S. None the less, the
meta-analyses including only high quality studies still show
increased absolute risk estimates, with similar risk distributions
(table 2⇓). Overall, for women with high risk thrombophilias,
risk estimates of pregnancy associated VTE have wide credible
intervals. This is caused by the low number of women with rare
thrombophilias investigated in studies and variable results
between studies. All available data were used because the
number of thrombotic events was low for the antepartum and
postpartum analyses. For protein C and protein S deficiency,
this causes a discrepancy between the antepartum, post partum,
and high quality overall risk estimates, which could change
treatment recommendations for protein C deficiency.
Non-family cohort studies rarely contain information on women
with high risk thrombophilias. The data therefore provide little
information on women with high risk thrombophilias who do
not have a positive family history of VTE. The most recent
study included in our review by Gerhardt et al21 was a
case-control study that provided absolute VTE risk estimates
in pregnant women with high risk thrombophilias regardless of
family history. However, unusual cut-off values (40-90% of
normal) for defining mild and severe deficiencies of
antithrombin, protein C, and protein S were used. Furthermore,
the calculation of absolute risk estimates from case-control data
required making assumptions of the absolute risk in control
women. The absolute VTE risk estimates for non-carriers in
their analyses (0.105-0.20%) did not take family setting or
non-family setting into account, which we have shown to differ
significantly (0.5% v 0.1%).
A limitation of our meta-analysis is that it did not account for
the changes in the methods of diagnosis of thrombophilia that
have occurred, especially for protein S deficiency,55 as we were
limited to the methods used in the individual studies. Preferably
studies require objective diagnosis of VTE. Using studies that
allowed treatment without objective diagnoses as a diagnostic
criterion for VTE is not optimal. However, data on rare
thrombophilias are sparse, and removing those studies in the
sensitivity analysis of odds ratio estimates did not show major
changes to the main results.
Strengths and weaknesses in relation to other
studies
This systematic review has identified the largest number of
studies on thrombophilia and pregnancy associated VTE so far,
including 41 297 pregnancies.8-58 When comparing the present
review on thrombophilia and pregnancy associated VTE with
the review by Robertson et al8 published in 2006, some
differences should be appreciated. The review by Robertson et
al included nine case-control studies, of which the latest was
reported in 2003. Fifteen out of 36 studies included in our study
predate 2003. This reflects a more inclusive search strategy.
Our meta-analysis, based on more data, revealed higher odds
ratios for pregnancy associated VTE for many thrombophilias,
compared with controls. These differences between both reviews
are important, as absolute risk estimates in current guidelines
are mainly based on the review by Robertson et al.9 10 In the
ACCP 2012 guidelines9 10 additional studies have been
reviewed.20-61 We excluded three of these additional studies
because they failed to meet the inclusion criteria of “separate
data per thrombophilia,”61 “objective VTE diagnosis,”60 and “no
use of VTE prophylaxis.”59 Nevertheless, our review included
36 studies, compared with 19 studies used in the ACCP 2012
guidelines. For women with deficiencies of antithrombin, protein
C, or protein S, the results of our meta-analysis show notably
higher relative and absolute risks of pregnancy associated VTE
compared with those in the ACCP guidelines. Lower absolute
risks were found for women with heterozygous factor V Leiden
or heterozygous prothrombin G20210A mutation.
Recommendations
In order to determine an acceptable number of women needed
to treat to prevent a VTE, the benefits of reducing the risk of
pregnancy associated VTE through treatment must be weighed
against the burdens of self injecting low molecular weight
heparins during a certain period. However, efficacy and optimal
doses of low molecular weight heparins prophylaxis are still a
matter of debate.62 Using data on hip arthroplasty, the ACCP
guidelines estimate the relative effects of prophylaxis using low
molecular weight heparins in women.9 A 2014 Cochrane review
found insufficient evidence on which to base recommendations
for dose and duration of thrombosis prophylaxis during
pregnancy and the postpartum period.63 To date, evidence on
prophylaxis using low molecular weight heparins in pregnant
women is insufficient to establish a number needed to treat. The
results of current prospective studies in women with
thrombophilia are eagerly awaited.64 65 In guidelines, thresholds
for prophylaxis using low molecular weight heparins of the
absolute risk of pregnancy associated VTE antepartum or
postpartum vary from 1% to 3%.10-67 It must be considered that
recommendations would differ considerably between thresholds
of 1% or 3% (see web appendix 1). In the most recent guideline,
experts set the threshold of the absolute risk of VTE for each
antepartum or postpartum period at 3% by consensus.10
Therefore, for our recommendations we also used this threshold
of 3% for each antepartum or postpartum period. We used all
study data for our recommendations because credible intervals
of all studies overlapped with those of high quality studies, and
because more study data allowed for more precise risk estimates.
Based on the thresholds of 3% and our meta-analyses, the
current ACCP 2012 guidelines9 and other guidelines as
summarised by Bates et al10 can be challenged regarding
thrombophilia. In the ACCP 2012 guidelines, prophylaxis using
low molecular weight heparins in both the antepartum and
postpartum period is only suggested for women with
homozygous factor V Leiden or homozygous prothrombin
G20210A mutations. We suggest antepartum prophylaxis and
prophylaxis up to six weeks post partum for women with no
previous VTE with antithrombin and protein C deficiency if
they have a positive family history. For women with
homozygous factor V Leiden mutations, thrombosis prophylaxis
may be considered for women with a family history and
additional risk factors for VTE, because the probabilities of
antepartum and postpartum VTE risk are 47% and 46%
respectively, and risk estimates from family studies are higher
than the risk estimates from non-family studies. For women
with protein S deficiency and a positive family history for VTE,
we suggest prophylaxis using low molecular weight heparins
only up to six weeks post partum. For homozygous prothrombin
G20210A mutation we cannot give recommendations because
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of the lack of cohort data and the poor correlation of odds ratios
with absolute risks. ACCP guidelines suggest thrombosis
prophylaxis both antepartum and post partum.9
In contrast with ACCP guidelines, for women with heterozygous
factor V Leiden or heterozygous prothrombin G20210A
mutations we suggest clinical vigilance only, even with a
positive family history of VTE. The same applies for women
with compound heterozygous factor V Leiden and prothrombin
G20210A mutations. Additional personal risk factors for VTE
such as obesity and immobilisation, should be taken into account
when deciding on thrombosis prophylaxis in individual patients.
Conclusions
In this systematic review and meta-analysis we show that all
women with inherited thrombophilia have an increased risk of
pregnancy associated VTE. We have calculated high absolute
risk estimates for pregnancy associated VTE for women with
deficiency of antithrombin, protein C, or protein S and a positive
family history for VTE, and for all women with homozygous
factor V Leiden mutation. Although further research is needed
for more precise risk estimates, in these women routine
thrombosis prophylaxis should be considered. The risk estimates
and chosen thresholds for treatment do not support routine use
of thrombosis prophylaxis in women with heterozygous factor
V Leiden or heterozygous prothrombin G20210A mutations or
compound heterozygous factor V Leiden and prothrombin
G20210A mutation. The data in this review should be considered
in future management guidelines on pregnancy associated VTE
risk in women with hereditary thrombophilia.
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Tables
Table 1| Relative risk of venous thromboembolism (VTE) associated with pregnancy
Probability
(%) of OR
No of studiesOdds ratios (95% CrI)No of
controls,
No of women
with
Thrombophilia
High
quality
AllHigh qualityRequiring
objectively
confirmed
VTE
CohortCase-controlAll >1 for high
quality
studies
with
VTE/Total*
thrombophilia,
with VTE/Total*
997108.9 (0.3 to
34.7)
7.9 (1.2 to
25.5)
25.9 (0.0 to
176.3)
5.0 (0.6 to
24.7)
9.5 (1.6 to
31.9)
710/217848/153Antithrombin
deficiency
996107.7 (0.0 to
48.1)
9.3† (2.1 to
43.1)
5.9 (0.0 to
49.6)
12.3 (0.0 to
139.8)
9.3 (2.1 to
43.1)
691/202449/180Protein C
deficiency
917106.9 (0.2 to
24.6)
7.0* (1.3 to
21.9)
7.2 (0.0 to
35.4)
6.7 (0.2 to
34.7)
7.0 (1.3 to
21.9)
700/221253/192Protein S
deficiency
10021276.4 (3.9 to
10.6)
5.9 (3.8 to 9.0)3.9 (0.2 to
11.9)
7.2 (4.3 to
12.6)
6.4 (4.0 to
9.7)
923/34 626305/3345Heterozygous
factor V Leiden
mutation
10091246.7 (4.1 to
193.1)
31.8 (0.2 to
145.3)
12.0 (0.0 to
69.9)
128.9 (3.0 to
3093.9)
35.8 (0.4 to
137.8)
919/26 90627/80Homozygous
factor V Leiden
mutation
10012154.3 (2.0 to
8.8)
4.5 (2.2 to 8.5)4.9 (0.0 to
23.7)
4.9 (2.0 to
11.4)
5.1 (2.6 to
9.8)
1002/21 73694/1433Heterozygous
prothrombin
G20210A
mutation
993413.4 (0.0 to
584.2)
14.8 (0.0 to
1052.9)
NA18.2 (0.0 to
1073.7)
21.1 (0.0 to
727.4)
559/19 6924/5Homozygous
prothrombin
G20210A
mutation
1007826.9 (1.1 to
147.1)
21.2† (1.6 to
89.0)
8.6 (0.5 to
62.3)
45.4 (0.6 to
478.6)
21.2 (1.6 to
89.0)
803/265245/242Compound
heterozygous
factor V Leiden
and prothrombin
G20210A
mutation
Odds ratios for pregnancy associated VTE for each thrombophilia compared with controls or non-carriers, including sensitivity analyses. Sensitivity analyses show
meta-analyses for each study type, meta-analyses of only studies requiring an objective VTE diagnosis, and of only high quality studies (NOS score ≥8). Final
column shows that the probability for the odds ratio being >1 for high quality studies are ≥99% for all thrombophilias. CrI=credible interval, NOS=Newcastle-Ottawa
scale, NA=not available. *Case-control and cohorts with non-carriers group. †All studies for this thrombophilia required objectively confirmed VTE.
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Table 2| Absolute risks (AR) of pregnancy associated venous thromboembolism (VTE) for each thrombophilia, for family and non-family
cohort studies
High quality studies% probability of AR
>3%, for all studies
% probability of AR
>1%, for all studies
AR of VTE, all studies, %
pregnancies (95% CrI)
No of VTE events
with information
No of women
with
No of
studies
Thrombophilia
on time of
occurrence/Total
thrombophilia
with VTE/Total AR of VTE,antepartum
and post
partum, %
pregnancies
(95% CrI)
No of women
with
thrombophilia
with VTE/Total
NoPost
partum
AntepartumPost
partum
AntepartumPost
partum
AntepartumAntepartum
and post
partum
Antithrombin
deficiency:
10.5 (0.0 to
30.3)
13/1053999610010011.1
(3.7 to
21.0)
7.3 (1.8 to
15.6)
16.6 (0.0 to
45.1)
23/2323/1254  Family
Protein C
deficiency:
2.6 (0.0 to
13.5)
4/1232835499965.4 (0.9
to 13.8)
3.2 (0.6 to
8.2)
7.8 (0.0 to
33.8)
10/1010/1373  Family
Protein S
deficiency:
3.6 (0.0 to
37.0)
6/130273998474.2 (0.7
to 9.4)
0.9 (0.0 to
3.7)
4.8 (0.0 to
20.0)
7/77/1353  Family
Heterozygous
factor V Leiden
mutation:
1.3 (0.5 to
2.2)
43/2604131109722.0 (0.9
to 3.7)
0.4 (0.1 to
0.9)
1.1 (0.3 to
1.9)*
37/4545/303117  Overall
2.4 (0.6 to
5.4)
33/1291625010032.5 (1.2
to 4.4)
0.4 (0.0 to
0.9)
2.4 (0.9 to
4.4)
34/3535/13598  Family
0.6 (0.0 to
1.2)
10/131372415310.4 (0.0
to 1.8)
0.7 (0.0 to
2.6)
0.4 (0.0 to
0.9)
3/1010/16729  Non-family
Homozygous
factor V Leiden
mutation:
7.9 (0.4 to
23.0)
5/565464785862.8 (0.0
to 8.8)
2.8 (0.0 to
8.6)
6.2 (0.0 to
18.0)
5/55/586  Overall
9.9 (0.0 to
39.7)
4/332NANANANANANA8.3 (0.0 to
29.6)
4/44/353  Family
5.6 (0.0 to
34.3)
1/233NANANANANANA5.6 (0.0 to
34.3)
1/11/233  Non-family
Heterozygous
prothrombin
G20210A
mutation:
0.9 (0.2 to
2.0)
14/13225104100.9 (0.2
to 2.0)
0.0 (0.0 to
0.2)
0.9 (0.2 to
2.0)
9/1414/13225  Overall
1.0 (0.0 to
2.5)
11/9984NANANANANANA1.0 (0.0 to
2.5)
9/1111/9984  Family
0.8 (0.1 to
2.0)
3/3241NANANANANANA0.8 (0.1 to
2.0)
0/33/3241  Non-family
Compound
heterozygous
factor V Leiden
and prothrombin
G20210A
mutation:
2.5 (0.0 to
9.5)
5/1993NANANANANANA2.5 (0.0 to
9.5)
3/55/1993  Family
Non-carriers,
overall:
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Table 2 (continued)
High quality studies% probability of AR
>3%, for all studies
% probability of AR
>1%, for all studies
AR of VTE, all studies, %
pregnancies (95% CrI)
No of VTE events
with information
on time of
occurrence/Total
No of women
with
thrombophilia
with VTE/Total
No of
studies
Thrombophilia
AR of VTE,
antepartum
and post
partum, %
pregnancies
(95% CrI)
No of women
with
thrombophilia
with VTE/Total
NoPost
partum
AntepartumPost
partum
AntepartumPost
partum
AntepartumAntepartum
and post
partum
0.4 (0.1 to
0.8)
12/229312NANANANANANA0.5 (0.2 to
1.0)
13/1414/233013  Family
0.1 (0.0 to
0.1)
18/307917NANANANANANA0.1 (0.0 to
0.1)
9/2020/312459  Non-family
Analyses shown are meta-analyses of absolute risks of all studies, including absolute risk of antepartum VTE and postpartum VTE, and meta-analyses of high quality studies (NOS score ≥8) only.
The probability of absolute risks of pregnancy associated VTE being above the treatment thresholds of 1% and 3% are also shown. CrI=credible interval, NOS=Newcastle-Ottawa scale, NA=not
available. *Significant effect of family studies as compared with non-family studies.
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Figure
Fig 1 Study selection process
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